Rationale for Treatment of mNSCLC with Immune Checkpoint Inhibitors

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to enhance early lung cancer detection.